"Bottom-line results were impacted by an unfavorable product mix of low and high margin product deliveries, additional headcount as we continue to invest in our sales and marketing team, and increased selling expenses as more distributors become engaged in selling our products. We expect that these impacts will be offset as we continue to grow revenues in the coming quarters."
Mr. McManus concluded, "The financial base of the Company continues to be strong with $6.9 million in cash and equivalents and zero long-term debt. We continue to make progress in expanding our business both domestically and internationally. While we are still in the early stages of executing on our plan as a focused medical device company, we are pleased with the progress made to date."
Conference Call:Michael A. McManus Jr., President and Chief Executive Officer, and Richard Zaremba, Senior Vice President and Chief Financial Officer, will host a conference call Thursday, February 7, 2013 at 4:30 pm ET to discuss the financial results of the first half of fiscal 2013.
Shareholders and other interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at www.misonix.com.
A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10024916. A webcast replay will be available in the Investor Relations section of the Company's website at www.misonix.com for 30 days.
About Misonix:Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis
|SOURCE Misonix, Inc.|
Copyright©2012 PR Newswire.
All rights reserved